We are live on ! Find out more
ALT icon

Altimmune

29 hedge funds and large institutions have $5.09M invested in Altimmune in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more capital inflows, than outflows

Capital inflows: $1.06M | Capital outflows: $413K

117% more call options, than puts

Call options by funds: $968K | Put options by funds: $447K

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

4% more funds holding

Funds holding: 28 → 29 (+1)

1.87% more ownership

Funds ownership: 8.46% → 10.32% (+1.9%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
29
Holders Change
+1
Holders Change %
+3.57%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
3
Reduced
4
Closed
8
Calls
$968​K
Puts
$447​K
Net Calls
+$521​K
Net Calls Change
+$463​K

ALT Hedge Fund Activity: Q1 2020 in Review

29 of the 4,552 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2020, worth a combined $5.09M — up 109% from $2.44M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ALT positions and 8 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.02M. The largest seller was Sabby Management, exiting entirely with an estimated $103K sold.

  • 29 institutional investors held Altimmune (ALT) as of Q1 2020, up from 28 in Q4 2019.
  • Funds reported $5.09M of Altimmune stock for Q1 2020, up 109% quarter-over-quarter.
  • 11 funds opened new Altimmune positions in Q1 2020 and 8 closed out, a net change of +3 holders.
  • The largest Altimmune buyer in Q1 2020 was Renaissance Technologies, an estimated $1.02M added.
  • The largest Altimmune seller in Q1 2020 was Sabby Management, an estimated $103K sold.

Based on aggregated 13F filings for Q1 2020.